Avertix Medical to go public via a SPAC merger with BIOS Acquisition in a $195m deal.

Avertix Medical, a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, agreed to go public via a SPAC merger with BIOS Acquisition, a special purpose acquisition company, in a $195m deal. "With its ability to detect early signs of a heart attack and alert patients and healthcare providers, the Guardian System has the potential to transform the approach to cardiac care and improve patient quality of life and outcomes. We are thrilled to join forces with BIOS to accelerate the commercialization, adoption and continued development of the Guardian System. We look forward to leveraging BIOS’ expertise and resources to bring this critical technology to more patients worldwide," Tim Moran, Avertix President and CEO.